89 related articles for article (PubMed ID: 29757003)
21. Transglutaminase type 2 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection.
Palucci I; Matic I; Falasca L; Minerva M; Maulucci G; De Spirito M; Petruccioli E; Goletti D; Rossin F; Piacentini M; Delogu G
J Intern Med; 2018 Mar; 283(3):303-313. PubMed ID: 29205566
[TBL] [Abstract][Full Text] [Related]
22. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
23. Anti-cancer activity of asiatic acid against human cholangiocarcinoma cells through inhibition of proliferation and induction of apoptosis.
Sakonsinsiri C; Kaewlert W; Armartmuntree N; Thanan R; Pakdeechote P
Cell Mol Biol (Noisy-le-grand); 2018 Jul; 64(10):28-33. PubMed ID: 30084792
[TBL] [Abstract][Full Text] [Related]
24. An unprecedented dual antagonist and agonist of human Transglutaminase 2.
Yi MC; Palanski BA; Quintero SA; Plugis NM; Khosla C
Bioorg Med Chem Lett; 2015 Nov; 25(21):4922-4926. PubMed ID: 26004580
[TBL] [Abstract][Full Text] [Related]
25. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Patt YZ; Hassan MM; Aguayo A; Nooka AK; Lozano RD; Curley SA; Vauthey JN; Ellis LM; Schnirer II; Wolff RA; Charnsangavej C; Brown TD
Cancer; 2004 Aug; 101(3):578-86. PubMed ID: 15274071
[TBL] [Abstract][Full Text] [Related]
26. Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma.
Braconi C; Swenson E; Kogure T; Huang N; Patel T
PLoS One; 2010 Dec; 5(12):e15195. PubMed ID: 21179572
[TBL] [Abstract][Full Text] [Related]
27. Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1/TS downregulation might be the mechanism.
Cai JP; Chen W; Hou X; Liang LJ; Hao XY; Yin XY
Anticancer Drugs; 2013 Nov; 24(10):1020-9. PubMed ID: 23941814
[TBL] [Abstract][Full Text] [Related]
28. Activation of transglutaminase 2 by nerve growth factor in differentiating neuroblastoma cells: A role in cell survival and neurite outgrowth.
Algarni AS; Hargreaves AJ; Dickenson JM
Eur J Pharmacol; 2018 Feb; 820():113-129. PubMed ID: 29242118
[TBL] [Abstract][Full Text] [Related]
29. TRAIL Enhances Shikonin Induced Apoptosis through ROS/JNK Signaling in Cholangiocarcinoma Cells.
Zhou G; Yang Z; Wang X; Tao R; Zhou Y
Cell Physiol Biochem; 2017; 42(3):1073-1086. PubMed ID: 28662515
[TBL] [Abstract][Full Text] [Related]
30. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
Saito Y; Muramatsu T; Kanai Y; Ojima H; Sukeda A; Hiraoka N; Arai E; Sugiyama Y; Matsuzaki J; Uchida R; Yoshikawa N; Furukawa R; Saito H
Cell Rep; 2019 Apr; 27(4):1265-1276.e4. PubMed ID: 31018139
[TBL] [Abstract][Full Text] [Related]
31. Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells.
Sydor S; Jafoui S; Wingerter L; Swoboda S; Mertens JC; Gerken G; Canbay A; Paul A; Fingas CD
World J Gastroenterol; 2017 Jun; 23(22):4007-4015. PubMed ID: 28652654
[TBL] [Abstract][Full Text] [Related]
32. Tissue transglutaminase-mediated chemoresistance in cancer cells.
Verma A; Mehta K
Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
[TBL] [Abstract][Full Text] [Related]
33. Gα(h)/transglutaminase-2 activity is required for maximal activation of adenylylcyclase 8 in human and rat glioma cells.
Obara Y; Yanagihata Y; Abe T; Dafik L; Ishii K; Nakahata N
Cell Signal; 2013 Mar; 25(3):589-97. PubMed ID: 23200849
[TBL] [Abstract][Full Text] [Related]
34. SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts.
Wang C; Lv H; Yang W; Li T; Fang T; Lv G; Han Q; Dong L; Jiang T; Jiang B; Yang G; Wang H
Cancer Lett; 2017 Jul; 398():1-11. PubMed ID: 28385602
[TBL] [Abstract][Full Text] [Related]
35. Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase.
van der Wildt B; Wilhelmus MM; Bijkerk J; Haveman LY; Kooijman EJ; Schuit RC; Bol JG; Jongenelen CA; Lammertsma AA; Drukarch B; Windhorst AD
Nucl Med Biol; 2016 Apr; 43(4):232-42. PubMed ID: 27067043
[TBL] [Abstract][Full Text] [Related]
36. Time to move to targeted drugs in biliary tract cancer?
Louvet C; Tournigand C
Onkologie; 2010; 33(1-2):10-1. PubMed ID: 20164655
[No Abstract] [Full Text] [Related]
37. Conformational changes and translocation of tissue-transglutaminase to the plasma membranes: role in cancer cell migration.
Kumar A; Hu J; LaVoie HA; Walsh KB; DiPette DJ; Singh US
BMC Cancer; 2014 Apr; 14():256. PubMed ID: 24725450
[TBL] [Abstract][Full Text] [Related]
38. Transglutaminase 2 and NF-kappaB interplay during NGF-induced differentiation of neuroblastoma cells.
Condello S; Caccamo D; Currò M; Ferlazzo N; Parisi G; Ientile R
Brain Res; 2008 May; 1207():1-8. PubMed ID: 18374307
[TBL] [Abstract][Full Text] [Related]
39. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
40. Lipopolysaccharide-Stimulated Transglutaminase 2 Expression Enhances Endocytosis Activity in the Mouse Microglial Cell Line BV-2.
Kawabe K; Takano K; Moriyama M; Nakamura Y
Neuroimmunomodulation; 2015; 22(4):243-9. PubMed ID: 25301694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
